MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

February 2, 2017
First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Link

February 1, 2017
MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs
Link

January 3, 2017
MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi
Link

December 2, 2016
MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Link